| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA954: Epcoritamab for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic treatments |
|
Medicine details |
|
| Medicine name | epcoritamab (Tepkinly®) |
| Formulation | 4 mg/0.8 ml concentrate for solution for injection; 48 mg solution for injection |
| Reference number | 5106 |
| Indication | Treatment of relapsed or refractory diffuse large B-cell lymphoma when a stem cell transplant has failed or is unsuitable |
| Company | AbbVie Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/01/2024 |
| NICE guidance | |